Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

FMXIN002 · NS002

Other · developed by Nasus Pharma

Phase 1/2 Most advanced trial
NSRX Developer
2 Registered trials

What is FMXIN002?

FMXIN002 (NS002) is a nasal powder spray of epinephrine microspheres, given as a single dose in one nostril. It is studied in allergy and anaphylaxis, including after a nasal allergen challenge.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
NS002
Drug type
Other
Therapy area
Immunology
Developer
Nasus Pharma (NSRX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07228325 Phase 1/2 Anaphylaxis Enrolling by invitation NSRX
NCT06205134 Phase 1/2 Anaphylaxis Completed NSRX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

AllergyAnaphylactic ReactionAnaphylaxis

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the NSRX page.

Follow NSRX, the company behind FMXIN002

See NSRX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

NSRX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.